<code id='A23E2AA967'></code><style id='A23E2AA967'></style>
    • <acronym id='A23E2AA967'></acronym>
      <center id='A23E2AA967'><center id='A23E2AA967'><tfoot id='A23E2AA967'></tfoot></center><abbr id='A23E2AA967'><dir id='A23E2AA967'><tfoot id='A23E2AA967'></tfoot><noframes id='A23E2AA967'>

    • <optgroup id='A23E2AA967'><strike id='A23E2AA967'><sup id='A23E2AA967'></sup></strike><code id='A23E2AA967'></code></optgroup>
        1. <b id='A23E2AA967'><label id='A23E2AA967'><select id='A23E2AA967'><dt id='A23E2AA967'><span id='A23E2AA967'></span></dt></select></label></b><u id='A23E2AA967'></u>
          <i id='A23E2AA967'><strike id='A23E2AA967'><tt id='A23E2AA967'><pre id='A23E2AA967'></pre></tt></strike></i>

          focus

          focus

          author:hotspot    Page View:51347
          Adobe

          The chief executive of the country’s biggest hospital chain said Thursday that labor costs are now lower as a percent of revenue than they were before the pandemic.

          “And again, that’s in the face of a very difficult labor market,” HCA Healthcare CEO Sam Hazen noted on the company’s second quarter earnings call. Health care providers and insurers are in the full swing of releasing their second-quarter earnings, and HCA tends to outperform its peers.

          advertisement

          Hospitals struggled with the high cost of nurses throughout the Covid-19 pandemic, but HCA on Thursday said several of its workforce initiatives are paying off.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          knowledge

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          FDA panel signals lack of confidence in Amgen cancer drug data
          FDA panel signals lack of confidence in Amgen cancer drug data

          AdobeTheclearanceofafirst-of-its-kindcancertreatmentmadebyAmgenisonshakiergroundfollowingaFoodandDru

          read more
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more

          Was Amgen transparent enough on FDA's concern on cancer drug?

          MarkJ.Terrill/APAmidthestunningrebukeAmgensufferedatthehandsoftheU.S.FoodandDrugAdministrationthiswe